Fundz
New|Fundz now works inside Claude2 min

Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

RedHill acquires Ferring's Rebyota and Clenpiq rights

PUBLIC · RDHLSep 01, 2026

Acquiring Company

RedHill Biopharma Ltd

Acquired Company

Ferring Pharmaceuticals

RaleighSaint-PrexManufacturingBiotechnologyHealthcareSoftwareHealth CareScience And EngineeringBiotechnologyHealth Care

Description

RedHill Biopharma announced the acquisition of exclusive global and U.S. commercialization rights to Ferring's Rebyota and Clenpiq. The deal, valued at $12 million upfront plus potential royalties, is part of RedHill's strategic repositioning in the gastrointestinal market. The drugs generated approximately $37.5 million in 2025 net sales, enhancing RedHill's commercial prospects and liquidity.

Company Information

Company

RedHill Biopharma Ltd

Location

Raleigh, North Carolina, United States

About

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal, infectious, and oncological diseases in the U.S. The company markets Talicia®, an FDA-approved treatment for H. pylori infection, and is advancing late-stage programs including opaganib, a first-in-class SPHK2 inhibitor; RHB-204 for Crohn’s disease and nontuberculous mycobacteria (NTM) infections; RHB-107 (upamostat) for COVID-19 and inflammatory diseases; and RHB-102 for nausea, vomiting, and IBS-D.

Fundz sees it the moment RedHill Biopharma Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Gilead
Likely contact at this company
••••••••@••••••••

See Gilead's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for RedHill Biopharma Ltd's next move

Learn about Strategic plan

Frequently asked

Who acquired Ferring Pharmaceuticals?

Ferring Pharmaceuticals was acquired by RedHill Biopharma Ltd, based in Raleigh. The deal was reported on September 1, 2026. RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal, infectious, and oncological diseases in the U.S. RedHill Biopharma Ltd is publicly traded (RDHL) and operates in Manufacturing.

When did RedHill Biopharma Ltd acquire Ferring Pharmaceuticals?

RedHill Biopharma Ltd's acquisition of Ferring Pharmaceuticals was reported on September 1, 2026. RedHill Biopharma announced the acquisition of exclusive global and U.S. commercialization rights to Ferring's Rebyota and Clenpiq. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Ferring Pharmaceuticals do?

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. It is privately held, operating in Biotechnology, and is based in Saint-Prex.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.